UK scientists have made a significant breakthrough in the fight against Huntington's disease, announcing that their new gene therapy, AMT-130, has successfully slowed the progression of the disease in early-stage trials. Conducted at University College London, the therapy demonstrated that some patients experienced a 75% slower decline over three years. This advancement is crucial as it offers hope for better management of a condition that has long been considered challenging to treat.

In a groundbreaking development, Huntington's disease has been successfully treated for the first time in the UK through a gene therapy trial. This innovative surgical procedure has shown to slow the progression of this devastating illness by an impressive 75% over three years. Huntington's disease, which is hereditary and leads to severe neurological decline, has long posed a significant challenge for patients and their families. This trial not only offers hope for those affected but also marks a significant step forward in the field of genetic medicine, potentially paving the way for future treatments.

A groundbreaking new gene therapy has shown remarkable results in slowing the progression of Huntington's disease by up to 75%. This significant advancement not only offers hope to those affected by this devastating condition but also represents a major step forward in genetic medicine, potentially paving the way for future treatments.